Cognitive and behavioral symptoms in mild to moderate Alzheimer's disease
Potential benefit studied: Possible improvement in measured cognitive and behavioral symptoms
Supporting researchA placebo-controlled human trial found that a boswellic-acid preparation improved cognitive and behavioural scores in people with mild to moderate Alzheimer’s disease.
Eighty-five people with Alzheimer's disease were randomized to K-Vie, a boswellic-acid preparation described as the main ingredient in Memowell, or placebo for six months. Researchers measured cognition, dementia severity, behavioral symptoms and selected blood markers.
K-Vie is a particular study preparation. Its findings cannot be transferred to Mobility's 100 mg Boswellia at 30% AKBA with moringa, and they do not establish cognitive benefits for this finished formula.
The doses above describe research, not personal dosing instructions. Ingredient studies do not diagnose symptoms or establish medical suitability. Discuss medicines, existing conditions and treatment decisions with an appropriate healthcare professional.